ReviewVeterinary medicine (Auckland, N.Z.)2016
Canine autoimmune hemolytic anemia: management challenges.
Review in Veterinary medicine (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- An HPLC-Based Multi-Analyte Secretome Characterization Panel for Canine Adipose-Derived Mesenchymal/Stromal Stem Cells: Quantification of Adenosine, Kynurenine, IL-10, and TGF-β in Conditioned Media-A Pilot Feasibility Study.International journal of molecular sciences · 2026Article
- Hyperbilirubinemia and neurologic signs in dogs with non-associative immune-mediated hemolytic anemia: 81 cases (2015-2024).Journal of veterinary internal medicine · 2026Article
- Development of Anti-Inflammatory Agents Utilizing DC-SIGN Mediated IL-10 Secretion in Autoimmune and Immune-Mediated Disorders: Bridging Veterinary and Human Health.International journal of molecular sciences · 2025Review
- Clinical presentation, outcome and prognostic factors in dogs with immune-mediated haemolytic anaemia: a retrospective single-centre study of 104 cases in Ireland (2002-2020).Irish veterinary journal · 2024Article
- Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia.Veterinary sciences · 2023Article
- Pulmonary thromboembolism due to immune-mediated hemolytic anemia in a cat: A serial study of hematology and echocardiographic findings.Frontiers in veterinary science · 2022Article
- Increased risk of select glucocorticoid adverse events in dogs of higher body weight.The Canadian veterinary journal = La revue veterinaire canadienne · 2022Article
- Breed predispositions, clinical findings, and prognostic factors for death in dogs with nonregenerative immune-mediated anemia.Journal of veterinary internal medicine · 2021Article
- Wound healing in immunocompromised dogs: A comparison between the healing effects of moist exposed burn ointment and honey.Veterinary world · 2020Article
- Leptospirosis and immune-mediated hemolytic anemia: A lethal association.Veterinary research forum : an international quarterly journal · 2019Article
- Methylprednisolone alone or combined with cyclosporine or mycophenolate mofetil for the treatment of immune-mediated hemolytic anemia in dogs, a prospective study.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated hemolytic anemia is one of the most common manifestations of canine immune-mediated disease, yet treatment regimens remain nonstandardized and, in some cases, controversial. The main reason for this, as for most diseases in veterinary medicine, is the lack of large-scale placebo-controlled trials so that the efficacy of one treatment over another can be established. Most of the evidence used for treatment comes from retrospective studies and from personal preference and experience, and because of this, treatment regimens tend to vary among institutions and individual clinicians. Management of immune-mediated hemolytic anemia includes immunosuppression, thromboprophylaxis, and supportive care measures to help prevent and treat concurrent conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.